Vectus Presenting at Bioshares Biotech Summit

Vectus Biosystems CEO Dr Tara Speranza presented at the Bioshares Biotech Summit in October 2026, sharing the Company’s development strategy with investors and other market participants.

Dr Speranza highlighted Vectus’ focus on advancing lead candidate VB0004 as a potential new treatment for idiopathic pulmonary fibrosis (IPF), alongside the broader opportunities for the Company’s technology and development pipeline.

Thank you to Bioshares for the opportunity to present and connect with the Australian biotech investment community.